ANIFROLUMAB, AN ANTI-INTERFERON-A RECEPTOR MONOCLONAL ANTIBODY IN SYSTEMIC LUPUS ERYTHEMATOSUS- A META ANALYSIS
Authors: A. Abdul Razzack et al.
Type I interferons have been implicated in the pathogenesis of SLE. To assess the efficacy and safety of Anifrolumab, a monoclonal antibody against type I interferon in SLE.a metanalysis was conducted from three studies with 839 participants (Anifrolumab=372, Placebo=467). Follow-up was 52 weeks. Anifrolumab was favoured over placebo in terms of BICLA response (OR 0.44; p < 0.00001), ≥50% reduction in CLASI activity score (OR 0.36;p=0.0001), glucocorticoid reduction (OR 0.41; p<0.00001) and SRI-4 response (OR 0.52; p=0.02). However, adverse events were less likely in the placebo arm as compared to Anifrolumab (OR 1.54; p=0.03).
Anifrolumab could become an interesting adjunct to our therapeutic armamentarium as this monoclonal antibody was found to be effective in reducing SLE activity. Anifrolumab may, however, also cause more severe adverse events.